Effects of Skeleton Structure of Mesoporous Silica Nanoadjuvants on Cancer Immunotherapy
© 2023 Wiley-VCH GmbH..
Mesoporous silica nanoparticles (MSNs) have been widely praised as nanoadjuvants in vaccine/tumor immunotherapy thanks to their excellent biocompatibility, easy-to-modify surface, adjustable particle size, and remarkable immuno-enhancing activity. However, the application of MSNs is still greatly limited by some severe challenges including the unclear and complicated relationships of structure and immune effect. Herein, three commonly used MSNs with different skeletons including MSN with tetrasulfide bonds (TMSN), MSN containing ethoxy framework (EMSN), and pure -Si-O-Si- framework of MSN (MSN) are comprehensively compared to study the impact of chemical construction on immune effect. The results fully demonstrate that the three MSNs have great promise in improving cellular immunity for tumor immunotherapy. Moreover, the TMSN performs better than the other two MSNs in antigen loading, cellular uptake, reactive oxygen species (ROS) generation, lymph node targeting, immune activation, and therapeutic efficiency. The findings provide a new paradigm for revealing the structure-function relationship of mesoporous silica nanoadjuvants, paving the way for their future clinical application.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Small (Weinheim an der Bergstrasse, Germany) - 20(2024), 3 vom: 18. Jan., Seite e2305567 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tan, Jia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
116XMU2GHK |
|---|
| Anmerkungen: |
Date Completed 19.01.2024 Date Revised 19.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/smll.202305567 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361994729 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361994729 | ||
| 003 | DE-627 | ||
| 005 | 20240119231858.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/smll.202305567 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1264.xml |
| 035 | |a (DE-627)NLM361994729 | ||
| 035 | |a (NLM)37702141 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tan, Jia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of Skeleton Structure of Mesoporous Silica Nanoadjuvants on Cancer Immunotherapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.01.2024 | ||
| 500 | |a Date Revised 19.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Wiley-VCH GmbH. | ||
| 520 | |a Mesoporous silica nanoparticles (MSNs) have been widely praised as nanoadjuvants in vaccine/tumor immunotherapy thanks to their excellent biocompatibility, easy-to-modify surface, adjustable particle size, and remarkable immuno-enhancing activity. However, the application of MSNs is still greatly limited by some severe challenges including the unclear and complicated relationships of structure and immune effect. Herein, three commonly used MSNs with different skeletons including MSN with tetrasulfide bonds (TMSN), MSN containing ethoxy framework (EMSN), and pure -Si-O-Si- framework of MSN (MSN) are comprehensively compared to study the impact of chemical construction on immune effect. The results fully demonstrate that the three MSNs have great promise in improving cellular immunity for tumor immunotherapy. Moreover, the TMSN performs better than the other two MSNs in antigen loading, cellular uptake, reactive oxygen species (ROS) generation, lymph node targeting, immune activation, and therapeutic efficiency. The findings provide a new paradigm for revealing the structure-function relationship of mesoporous silica nanoadjuvants, paving the way for their future clinical application | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cancer vaccines | |
| 650 | 4 | |a cellular immunity | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a mesoporous silica nanoadjuvant | |
| 650 | 4 | |a skeleton structures | |
| 650 | 7 | |a Silicon Dioxide |2 NLM | |
| 650 | 7 | |a 7631-86-9 |2 NLM | |
| 650 | 7 | |a tetramethylsuccinonitrile |2 NLM | |
| 650 | 7 | |a 116XMU2GHK |2 NLM | |
| 650 | 7 | |a Nitriles |2 NLM | |
| 700 | 1 | |a Ding, Binbin |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Chunzheng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Wenying |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xinyang |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Di |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Pan |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Ping'an |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Jun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Small (Weinheim an der Bergstrasse, Germany) |d 2005 |g 20(2024), 3 vom: 18. Jan., Seite e2305567 |w (DE-627)NLM167400452 |x 1613-6829 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2024 |g number:3 |g day:18 |g month:01 |g pages:e2305567 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/smll.202305567 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2024 |e 3 |b 18 |c 01 |h e2305567 | ||